Business Context and Reporting Period
This Form 8-K Current Report was filed by Coherus BioSciences, Inc. (trading symbol: CHRS) on December 11, 2023, covering events occurring on December 7, 8, and 9, 2023. The filing addresses significant changes in the company's executive leadership, specifically within the finance function.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance data.
Material Changes
- Resignation of CFO: McDavid Stilwell resigned as Chief Financial Officer, Principal Financial Officer, and employee, effective December 31, 2023, to pursue other opportunities.
- Appointment of Interim CFO: Bryan McMichael was appointed as Interim Chief Financial Officer and Principal Financial Officer, effective December 8, 2023.
- Internal Promotion: Mr. McMichael previously served as Executive Vice President, Accounting, Corporate Controller, and Principal Accounting Officer since September 2022.
Guidance, Outlook, and Risks
The filing contains no financial guidance, market outlook, or discussion of operational risks. Regarding contingencies and unusual items, the company confirmed there are no family relationships between Mr. McMichael and any directors or officers, and no transactions requiring disclosure under Item 404(a) of Regulation S-K. No new compensation grants or awards were issued in connection with the interim appointment, though a standard indemnification agreement remains in effect.
Investor Verification Checklist
- Verify the transition timeline for the CFO role between December 8 and December 31, 2023.
- Review Mr. McMichael's prior experience at Gilead Sciences and NetApp to assess continuity in financial oversight.
- Confirm that no undisclosed compensation arrangements exist for the interim role.
- Monitor future filings for the appointment of a permanent Chief Financial Officer.